drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting CD5; antigen binding triggers CAR signaling (CD3ζ/co-stimulatory domains) leading to expansion and cytotoxic killing of CD5-positive malignant T cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor targeting CD5; antigen binding triggers CD3ζ and co‑stimulatory signaling, driving T‑cell activation, expansion, and perforin/granzyme‑mediated cytotoxic killing of CD5‑positive malignant T cells.
drug_name
CD5-directed CAR T cells
nct_id_drug_ref
NCT06420076